These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36820905)

  • 1. Pain: a neglected symptom in hemophilia.
    Kurçaloğlu M; Atay MH
    Ann Hematol; 2023 Apr; 102(4):947-953. PubMed ID: 36820905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
    Olasupo OO; Lowe MS; Krishan A; Collins P; Iorio A; Matino D
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014201. PubMed ID: 34407214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study.
    Shapiro AD; Donfield SM; Lynn HS; Cool VA; Stehbens JA; Hunsberger SL; Tonetta S; Gomperts ED;
    Pediatrics; 2001 Dec; 108(6):E105. PubMed ID: 11731632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The orthopaedic status of severe haemophiliacs in Spain.
    Aznar JA; Magallón M; Querol F; Gorina E; Tusell JM
    Haemophilia; 2000 May; 6(3):170-6. PubMed ID: 10792475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
    Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
    J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Unsolved issues of treatment of adult patients with hemophilia A].
    Zozulya NI; Dimitrieva OS
    Ter Arkh; 2022 Jan; 94(1):77-82. PubMed ID: 36286921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) study.
    Batt K; Boggio L; Neff A; Buckner TW; Wang M; Quon D; Witkop M; Recht M; Kessler C; Iyer NN; Cooper DL
    Eur J Haematol; 2018 Apr; 100 Suppl 1():14-24. PubMed ID: 29498783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis.
    Escobar M; Sallah S
    J Thromb Haemost; 2013 Aug; 11(8):1449-53. PubMed ID: 23763284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors.
    Leissinger CA; Singleton T; Kruse-Jarres R
    Blood; 2015 Jul; 126(2):153-9. PubMed ID: 25827834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence.
    Ghosh K; Ghosh K
    Expert Rev Hematol; 2021 Aug; 14(8):721-730. PubMed ID: 34278926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The specific features of pain syndrome in patients with hemophilia].
    Levchenko OK; Shulutko EM; Zorenko VY; Galstyan GM
    Ter Arkh; 2016; 88(7):84-88. PubMed ID: 27459620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of replacement therapies with clotting factors in patients with hemophilia: A systematic review and meta-analysis.
    Delgado-Flores CJ; García-Gomero D; Salvador-Salvador S; Montes-Alvis J; Herrera-Cunti C; Taype-Rondan A
    PLoS One; 2022; 17(1):e0262273. PubMed ID: 35030189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern management of haemophilic arthropathy.
    Raffini L; Manno C
    Br J Haematol; 2007 Mar; 136(6):777-87. PubMed ID: 17341263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future.
    Rodriguez-Merchan EC
    Expert Rev Hematol; 2022 Sep; 15(9):821-831. PubMed ID: 35930399
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.